Millions at risk for serious problems like uncontrolled bleeding or developing blood clots
Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.
This could put them at risk for serious problems like uncontrolled bleeding or developing blood clots.
Millions of Americans with coronary artery disease take one of the two drugs - clopidogrel (Plavix) and prasugrel (Effient) - to prevent harmful blood clots that can cause a stroke or heart attack. Current guidelines recommend that all patients take the same standardized dose. But in this new study of 521 patients, researchers at the Intermountain Medical Center Heart Institute found that dose is not effective for all patients.
"There's a sweet spot, an appropriate range for each patient. But we found that not many people are falling into that range," said cardiologist Brent Muhlestein, MD, a cardiac researcher at the Intermountain Medical Center Heart Institute.
Dr. Muhlestein is presenting the group's findings on Nov. 6 at the American Heart Association Scientific Sessions 2012 in Los Angeles.
"We showed that by performing a simple blood test to see whether or not the blood is clotting properly, we can determine whether patients are getting an appropriate, individualized dose of the medications," he says. "The test is easy to perform, but not widely used."
The Intermountain Medical Center Heart Institute study could help lead to personalized treatment and improved results for millions of people taking the drugs. It may also help cut pharmacy bills for many patients. The annual cost for one of the medications is more than $1,800. Finding the lowest effective dose for those patients could conceivably cut their bill in half.
Major findings of the study show that: